Members of our team had the opportunity to present a new poster abstract at the  2020 NASP Annual Meeting & Expo, which was held virtually from September 14-18. Lily Duong, PharmD, RPh, Chief Clinical Officer at CPS, along with Khang Tran, PharmD, and Abbas Dewji, PharmD, presented the abstract Impact of Specialty Pharmacies on Stomatitis Prophylaxis with Dexamethasone at Everolimus Therapy Initiation on Wednesday, September 16.

Background

A 2017 SWISH trial concluded that prophylactic use of dexamethasone mouthwash reduced the incidence and severity of stomatitis of patients on Everolimus (Afinitor®). Thereafter everolimus prescribing information was updated to include use of dexamethasone at everolimus initiation. Specialty pharmacies (SPs) are in a unique position to ensure patients start therapy appropriately to reduce adverse events, increase adherence, and improve outcomes.

Objectives

Observe the impact of specialty pharmacies on improving outcomes and quality of care for patients via access to dexamethasone upon initiating everolimus.

Read about the team's results by downloading the Outcomes Study below.

Download the abstract: